Laura K Hilton, Brett J Collinge, Susana Ben-Neriah, Waleed Alduaij, Haya Shaalan, Andrew Weng, Manuela Cruz, Graham W Slack, Pedro Farinha, Tomoko Miyata-Takata, Merrill Boyle, Barbara Meissner, James R Cook, Sarah L Ondrejka, German Ott, Andreas Rosenwald, Elías Campo, Catalina Amador, Timothy C Greiner, Philipp W Raess, Joo Y Song, Giorgio Ga Inghirami, Elaine S Jaffe, Dennis D Weisenburger, Wing C Chan, Klaus Beiske, Kai Fu, Jan Delabie, Stafania Pittaluga, Javeed Iqbal, George Wright, Laurie H Sehn, Kerry J Savage, Andrew J Mungall, Andrew L Feldman, Louis M Staudt, Christian Steidl, Lisa M Rimsza, Ryan D Morin, David W Scott
Rearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both MYC and BCL2 rearrangements are classified as high-grade B-cell lymphoma with MYC and BCL2 rearrangements ("double hit": HGBCL-DH-BCL2) and are associated with aggressive disease and poor outcomes. Although it is established that MYC rearrangements involving immunoglobulin (IG) loci are associated with inferior outcomes relative to those involving other non-IG superenhancers, the frequency of, and mechanisms driving, IG vs non-IG MYC rearrangements have not been elucidated...
May 3, 2024: Blood